As its oncology effort gathers steam, AstraZeneca sheds another legacy drug
On the day AstraZeneca suffered a setback after the US regulator rejected its triplet for chronic obstructive pulmonary disease — it also palmed off the rights to a legacy treatment, Losec, to Germany’s Cheplapharm Arzneimittel GmbH in a deal worth $243 million upfront.
Losec contains the active ingredient omeprazole and belongs to a class of drugs called proton pump inhibitors that are engineered to work by diminishing the level of acid the stomach produces. It has a number of approved indications and is commonly prescribed for patients with gastro-oesophageal reflux disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.